EP Patent

EP3981399A1 — Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor

Assigned to BeOne Medicines I GmbH · Expires 2022-04-13 · 4y expired

What this patent protects

Provided are an oral solid tablet comprising (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo [1,5 -a]pyrimidine-3 -carboxamide and preparation method therefor. The oral solid tablet has good drug release characteristics, features easy administratio…

USPTO Abstract

Provided are an oral solid tablet comprising (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo [1,5 -a]pyrimidine-3 -carboxamide and preparation method therefor. The oral solid tablet has good drug release characteristics, features easy administration, quick and high-efficient release, no particular requirements on equipment, and a simple formulation preparation process, can ensure formulation stability and facilitate transportation and storage, and is suitable for large-scale production.

Drugs covered by this patent

Patent Metadata

Patent number
EP3981399A1
Jurisdiction
EP
Classification
—
Expires
2022-04-13
Drug substance claim
No
Drug product claim
No
Assignee
BeOne Medicines I GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.